The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Limitations of post-hoc analysis in guideline development for colorectal cancer
Marco Germani, MD, FRCP, University of Pisa, Pisa, Italy, emphasizes that findings from post-hoc analyses cannot currently influence clinical guidelines for colorectal cancer management. There is a pressing need for improved predictive models for early disease progression and while some patients respond well to first-line treatments, not all require immediate reassessment. Due to the lower grade of evidence from these analyses, substantial changes to current practices are unlikely at this time. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
